Clinical Trials Browser

Phase 3 × Gefitinib × Genitourinary × Clear all

NCT00352079 2023-08-04

BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer

Phase 3 Terminated

Urinary Bladder Neoplasms